Next-generation sequencing for measuring minimal residual disease in AML

Next-generation sequencing for measuring minimal residual disease in AMLNext-generation sequencing for measuring minimal residual disease in AML, Published online: 23 May 2018; doi:10.1038/s41571-018-0040-0The prognostic significance of residual disease, measured by flow cytometry or PCR-based assays, has been established in patients with acute myeloid leukaemia (AML). The results of a recent study involving almost 500 patients in morphological remission demonstrate that detection of persistent mutations using next-generation sequencing provides information complementary to that obtained using the established methods and offer insights into AML evolution.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research